Restricted accessResearch articleFirst published online 2014-11
Ethyl-3,4-Dihydroxybenzoate with a Dual Function of Induction of Osteogenic Differentiation and Inhibition of Osteoclast Differentiation for Bone Tissue Engineering
The current approach in biomaterial design of bone implants is to induce in situ regeneration of bone tissue, thus improving integration of the implants and reducing their failure. Therefore, ethyl-3,4-dihydroxybenzoate (EDHB), which stimulates differentiation of osteoblasts and the resultant bone formation, should be studied. In this study, the osteoinductive ability of EDHB in preosteoblasts and human mesenchymal stem cells was examined. EDHB for future use in bone tissue engineering was evaluated by examination of early markers of differentiation (such as alkaline phosphatase [ALP] activity and collagen type I expression) and late markers of osteoblast differentiation (bone nodule formation). As bone remodeling and implant osteointegration depend not only on osteoblast response but also on interaction of the biomaterial with bone-resorbing osteoclasts, differentiation of osteoclasts in response to the compounds was also observed. For in vivo study, alginate gel comprised of EDHB and cells was transplanted into the back subcutis of mice. Our results show that EDHB might have beneficial effects through regulation of both osteoblast and osteoclast differentiation. Therefore, we suggest that EDHB could be a strong candidate for dual regulation to increase osteoblast differentiation and decrease osteoclast differentiation.
Get full access to this article
View all access options for this article.
References
1.
HenchL.L., and PolakJ.M.Third-generation biomedical materials. Science, 295, 1014, 2002.
2.
CowanC.M., SooC., TingK., and WuB.Evolving concepts in bone tissue engineering. Curr Top Dev Biol, 66, 239, 2005.
3.
KanakarisN.K., PaliobeisC., NlanidakisN., and GiannoudisP.V.Biological enhancement of tibia diaphyseal aseptic non-unions: the efficacy of autologous bone grafting, BMPs and reaming by-products. Injury, 38, S65, 2007.
4.
ChenC.H., HoM.L., ChangJ.K., HungS.H., and WangG.J.Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporos Int, 16, 2039, 2005.
5.
ValiB., RaoL.G., and El-SohemyA.Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. J Nutr Biochem, 18, 341, 2007.
6.
KimY.J., BaeY.C., SuhK.T., and JungJ.S.Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem Pharmacol, 72, 1268, 2006.
7.
DaiZ., LiY., QuarlesL.D., SongT., PanW., ZhouH., and XiaoZ.Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER- dependent ERK1/2 activation. Phytomedicine, 14, 806, 2007.
8.
de BoerJ., LichtR., BongersM., van der KlundertT., ArendsR., and van BlitterswijkC.Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng, 12, 2927, 2006.
9.
ChoH.H., ParkH.T., KimY.J., BaeY.C., SuhK.T., and JungJ.S.Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem, 96, 533, 2005.
10.
DoS.H., LeeJ.W., JeongW.I., ChungJ.Y., ParkS.J., and HongI.H.Bone-protecting effect of Rubus coreanus by dual regulation of osteoblasts and osteoclasts. Menopause, 15, 676, 2008.
11.
SasakiT., MajamaaK., and UittoJ.Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate: inhibition of prolyl hydroxylase activity as a mechanism of action. J Biol Chem, 262, 9397, 1987.
12.
RocnikE.F., ChanB.M., and PickeringJ.G.Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. J Clin Invest, 101, 1889, 1998.
13.
NandanD., ClarkeE.P., BallE.H., and SanwalB.D.Ethyl-3,4-dihydroxybenzoate inhibits myoblast differentiation: evidence for an essential role of collagen. J Cell Biol, 110, 1673, 1990.
14.
LiB., TakedaK., YokoyamaS., and ShibaharaS.A prolyl-hydroxylase inhibitor, ethyl-3,4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. J Biochem, 144, 643, 2008.
15.
SuzukiY., TaniharaM., SuzukiK., SaitouA., SufanW., and NishimuraY.Alginate hydrogel linked with synthetic peptide derived from BMP-2 allows ectopic osteoinduction in vivo. J Biomed Mater Res, 50, 405, 2000.
16.
ZhaoJ., OhbaS., KomiyamaY., ShinkaiM., ChungU.I., and NagamuneT.Icariin: a potential osteoinductive compound for bone tissue engineering. Tissue Eng Part A, 16, 233, 2010.
17.
GotohM., NotoyaK., IenaqaY., KawaseM., and MakinoH.Enhancement of osteogenesis in vitro by a novel osteoblast differentiation-promoting compound, TAK-778, partly through the expression of Msx2. Eur J Pharmacol, 451, 19, 2002.
18.
BalakrishnanB., and JayakrishnanA.Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffold. Biomaterials, 26, 3941, 2005.
19.
ManY., WangP., GuoY., XiangL., YangY., QuY., GongP., and DengL.Angiogenic and osteogenic potential of platelet-rich plasma and adipose-derived stem cell laden alginate microspheres. Biomaterials, 33, 8802, 2012.
20.
LeeC.S., MoyerH.R., GittensR.A., WilliamsJ.K., BoskeyA.L., BoyanB.D., and SchwartzZ.Regulating in vivo calcification of alginate microbeads. Biomaterials, 31, 4926, 2010.
21.
OrbanJ.M., MarraK.G., and HollingerJ.O.Composition options for tissue-engineered bone. Tissue Eng, 8, 529, 2002.
22.
HeinoT.J., and HentunenT.A.Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther, 3, 131, 2008.
23.
JaiswalN., HaynesworthS.E., CaplanA.I., and BruderS.P.Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem, 64, 295, 1997.
24.
KramperaM., PizzoloG., ApriliG., and FranchiniM.Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone, 39, 678, 2006.
25.
MarieP.J., and FromigueO.Osteogenic differentiation of human marrow-derived mesenchymal stem cells. Regen Med, 1, 539, 2006.
26.
PittengerM.F., MackayA.M., BeckS.C., JaiswalR.K., DouglasR., MoscaJ.D., MoormanM.A., SimonettiD.W., Craig.S., and MarshakD.R.Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143, 1999.
27.
BeierJ.P., BittoF.F., LangeC., KlumppD., ArkudasA., BleizifferO., BoosA.M., HorchR.E., and KneserU.Myogenic differentiation of mesenchymal sem cells co-cultured with primary muoblasts. Cell Biol Int, 35, 397, 2011.
28.
StocumD.L.Stem cells in regenerative biology and medicine. Wound Repair Regen, 9, 429, 2001.
29.
YooJ.U., and JohnstoneB.The role of osteochondral progenitor cells in fracture repair. Clin Orthop Relat Res, 355, S73, 1998.
30.
BruderS.P., JaiswalN., and HaynesworthS.E.Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem, 64, 278, 1997.
PoradaC.D., ZanjaniE.D., and Almeida-PoradG.Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther, 1, 365, 2006.
33.
RodanG.A., and MartinT.J.Therapeutic approaches to bone disease. Science, 289, 1508, 2000.
34.
CuetaraB.L., CrottiT.N., O'DonoqhueA.J., and McHughK.P.Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim, 42, 182, 2006.
35.
OrrissI.R., UttingJ.C., Brandao-BurchA., ColstonK., GrubbB.R., BurnstockG., and ArnettT.R.Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology, 148, 4208, 2007.
36.
KomoriT., YagiH., NomuraS., YamaguchiA., SasakiK., DeguchiK., ShimizuY., BronsonR.T., GaoY.H., InadaM., SatoM., OkamotoR., KitamuraY., YoshikiS., and KishimotoT.Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755, 1997.
37.
AubinJ.E., and TriffittJ.T.Mesenchymal stem cells and osteoblast differentiation. In: BilezikianJ.P., RaiszL.G., and RodanG.A., eds. Principles of Bone Biology: 2nd ed. New York: Academic Press, 2002, pp. 59–81.
38.
KatagiriT., and TakahashiN.Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis, 8, 147, 2002.
39.
KarstM., GornyG., GalvinR.J., and OurslerM.J.Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol, 200, 99, 2004.
40.
HigashinakagawaM.Biological effects of basic fibroblast growth factor (bFGF) and osteogenic protein-1 (OP-1/BMP-7) on bone marrow cells and development of cell-hybrid artificial bone. Kokubyo Gakkai Zasshi, 66, 118, 1999.
41.
SaitoN., OkadaT., HoriuchiH., OtaH., TakahashiJ., MurakamiN., NawataM., KojimaS., NozakiK., and TakaokaK.Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone, 32, 381, 2003.
42.
LangerR., and VacantiJ.P.Tissue engineering. Science, 260, 920, 1993.
43.
MierischC.M., WilsonH.A., TurnerM.A., MilbrandtT.A., BerthouxL., HammarskjöldM.L., RekoshD., BalianG., and DiduchD.R.Chondrocyte transplantation into articular cartilage defects with use of calcium alginate: the fate of the cells. J Bone Joint Surg Am, 85-A, 1757, 2003.
44.
ParkD.J., ChoiB.H., ZhuS.J., HuhJ.Y., KimB.Y., and LeeS.H.Injectable bone using chitosan-alginate gel/mesenchymal stem cells/BMP-2 composites. J Craniomaxillofac Surg, 33, 50, 2005.
45.
WeeS., and GombotzW.R.Protein release from alginate matrices. Adv Drug Deliv Rev, 31, 267, 1998.
46.
TønnesenH.H., and KarlsenJ.Alginate in drug delivery systems. Drug Dev Ind Pharm, 28, 621, 2002.
47.
CovielloT., MatricardiP., MarianecciC., and AlhaiqueF.Polysaccharide hydrogels for modified release formulations. J Control Release, 119, 5, 2007.
48.
LeeK.Y., PetersM.C., and MooneyD.J.Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release, 87, 49, 2003.
49.
GarimellaR., TagueS.E., ZhangJ., BelibiF., NaharN., SunB.H., InsognaK., WangJ., and AndersonH.C.Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J Histochem Cytochem, 56, 569, 2008.
50.
KohA.J., DemiralpB., NeivaK.G., HootenJ., NohutcuR.M., ShimH., DattaN.S., TaichmanR.S., and McCauleyL.K.Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology, 146, 4584, 2005.
51.
MartinT.J., and SimsN.A.Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med, 11, 76, 2005.
52.
KarsdalM.A., Neutzsky-WulffA.V., DziegielM.H., ChristiansenC., and HenriksenK.Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun, 366, 483, 2008.
53.
KarsdalM.A., MartinT.J., BollerslevJ., ChristiansenC., and HenriksenK.Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res, 22, 487, 2007.
54.
BernhardtA., ThiemeS., DomaschkeH., SpringerA., Rösen-WolffA., and GelinskyM.Crosstalk of osteoblast and osteoclast precursors on mineralized collagen—towards an in vitro model for bone remodeling. J Biomed Mater Res A, 95, 848, 2010.
55.
ThomasG.P., BakerS.U., EismanJ.A., and GardinerE.M.Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol, 170, 451, 2001.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
